Arca
Skip to content

Ewing sarcoma

Drug research and approvals for ewing sarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 58 studies of ewing sarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 7 open orphan designations naming it.

  • Recruiting worldwide: 58
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 58 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

12 in phase 3, 13 in phase 2, 16 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Irinotecan
Phase 3 DNA topoisomerase I inhibitor
Temozolomide
Phase 3 DNA inhibitor
Vincristine
Phase 3 Tubulin inhibitor
Cyclophosphamide anhydrous
Phase 3 DNA inhibitor
Busulfan
Phase 3 DNA inhibitor
Doxorubicin
Phase 3 DNA topoisomerase II alpha inhibitor
Ifosfamide
Phase 3 DNA inhibitor
Modafinil
Phase 3 Dopamine transporter inhibitor
Treosulfan
Phase 3 DNA cross-linking agent
Zoledronic acid anhydrous
Phase 3 Farnesyl diphosphate synthase inhibitor
Dactinomycin
Phase 3 DNA inhibitor
Filgrastim
Phase 2 Granulocyte colony stimulating factor receptor agonist
Dexrazoxane
Phase 2 Iron sequestering agent
Topotecan
Phase 2 DNA topoisomerase I inhibitor
Olaparib
Phase 2 PARP 1, 2 and 3 inhibitor
Docetaxel anhydrous
Phase 2 Tubulin inhibitor
Naxitamab
Phase 2 Disialoganglioside GD2 binding agent
Gemcitabine
Phase 2 Ribonucleoside-diphosphate reductase RR1 inhibitor
Indinavir anhydrous
Phase 2 Human immunodeficiency virus type 1 protease inhibitor
Palbociclib
Phase 2 CDK6/cyclin D1 inhibitor
Linsitinib
Phase 2 Insulin-like growth factor I receptor inhibitor
Ganitumab
Phase 2 Insulin-like growth factor I receptor antagonist
Figitumumab
Phase 1 Insulin-like growth factor I receptor antagonist
Lurbinectedin
Phase 1 DNA negative modulator
Interferon GAMMA-1B
Phase 1 Interferon gamma receptor agonist
Plicamycin
Phase 1 DNA inhibitor

Showing the 30 furthest along of 41 in trials.

How Its Trials Ended

264 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 57 whose ending is known, 18% met their primary endpoint, 16% missed it and 67% stopped early.

  • Completed, result not reported10741%
  • Ongoing8331%
  • Stopped: other or unclear197%
  • Status unknown176%
  • Met its primary endpoint104%
  • Stopped: enrollment or feasibility104%
  • Missed its primary endpoint93%
  • Stopped: sponsor or business decision52%
  • Stopped: lack of efficacy31%
  • Stopped: funding10%

FDA Orphan Designations

Approved first, then open designations, newest first
Apr 25, 2025Dinutuximab betaTreatment of Ewing sarcomaRecordati Rare Diseases Inc.Designated
Oct 22, 2024Small molecule RBM39-degraderTreatment of Ewing sarcomaSEED Therapeutics Inc.Designated
Jul 9, 2024PadnarsertibTreatment of Ewing sarcomaKaryopharm Therapeutics Inc.Designated
Jan 5, 2021Cu-64 anti CD99Diagnostic for the clinical management of Ewing SarcomaAdvanced Imaging Projects, LLCDesignated
Jul 7, 2020A novel humanized bispecific XmAb T cell recruiting…Treatment of Ewing SarcomaAmgen, Inc.Designated
Jun 30, 2016Small molecule Ewing Sarcoma breakpoint region 1/Friend…Treatment of Ewing sarcomaGeorgetown UniversityDesignated
Jul 7, 2015ANA-conjugated dactunomycin nanoemulsionTreatment of Ewing sarcomaNanoSmart Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.